Get all your news in one place.
100's of premium titles.
One app.
Start reading
AAP
AAP
Health
Derek Rose

ASX drug companies applaud TGA's psychedelic ruling

Little Green Pharma plans a clinical trial to evaluate the use of psilocybin to treat depression. (PR HANDOUT IMAGE PHOTO) (AAP)

ASX-listed small-cap drug companies are soaring as two firms announce plans to take advantage of Australia's medical regulator relaxing the rules around two mind-altering drugs.

The Therapeutic Goods Administration on Friday announced it was down-scheduling psilocybin and MDMA, allowing both to dispensed as of July 1 by authorised psychiatrists to treat certain mental health conditions.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.